Command Palette
Search for a command to run...
Pociredir in sickle cell disease: an EED inhibitor halted by a PRC2 class-safety verdict
Pociredir raised fetal hemoglobin by inhibiting the PRC2 subunit EED, a phenotype that is among the best-validated in hematology, but the program was discontinued after the FDA judged PRC2-class malignancy risk unacceptable for a chronic non-malignant disease.
Mechanism Risk Score
| Component | Points |
|---|---|
| Phase-weighted failure burden | 4.7 / 40 |
| Archetype severity | 8.5 / 25 |
| Temporal recency | 4.3 / 15 |
| Genetic evidence deficit | 15.0 / 15 |
| Programmatic saturation | 2.5 / 5 |
For EED in Sickle cell disease, the Mechanism Risk Score is 35/100 (yellow band). The score is a failure-burden index derived from Claidex post-mortems on this target–disease pair, not a probability of approval.
MRS 35/100 (YELLOW). 1 programs across EED have been documented for EED in Sickle cell disease: 0 Phase 3, 0 Phase 2, 1 Phase 1 — of which 0 were efficacy failures, 1 safety, 0 biomarker, and 0 operational (enrollment, sponsor, or funding). The most informative failure on file is Pociredir in sickle cell disease: an EED inhibitor halted by a PRC2 class-safety verdict. This score quantifies the documented failure burden; the Open Targets association score of 0.00 reflects weak genetic anchoring, compounding the documented failure record. The MRS is not a prediction of future trial outcomes — it is a structured summary of the empirical record, recomputed live from the Claidex claims table, and intended to flag mechanisms where any new program must explicitly resolve each prior failure mode before pursuit is justified.
This score does not predict whether the next trial will succeed. It flags how heavy the documented mechanistic failure record is before a new program is justified.
What was tried
Fulcrum Therapeutics developed pociredir, formerly FTX-6058, an oral small-molecule inhibitor of embryonic ectoderm development (EED), a core subunit of the polycomb repressive complex 2 (PRC2). The goal was to raise fetal hemoglobin (HbF) in sickle cell disease. The trial covered here, NCT07431398, was an open-label Phase 1 study of single-dose pharmacokinetics under fasted and fed conditions in 13 participants with sickle cell disease. It was terminated, with the posted reason recorded as Sponsor decision and an actual primary completion date of 1 June 2026 (ClinicalTrials.gov). On the same day, Fulcrum announced discontinuation of the entire pociredir program and a strategic review (Fulcrum press release, 1 June 2026).
The biological hypothesis
The phenotype pociredir aimed for is one of the most thoroughly validated in hematology. Fetal hemoglobin dilutes sickle hemoglobin and reduces polymerization, so raising HbF lowers vaso-occlusion. BCL11A is the master transcriptional repressor that silences gamma-globin after birth, and removing that repression reactivates HbF. A first-in-human gene therapy that knocked down BCL11A in erythroid cells produced 71 percent F-cells and 11.9 pg HbF per F-cell, stable for at least 48 months in 9 of 10 treated patients, with sustained reduction of vaso-occlusive events (Blood 2026, 10.1182/blood.2026033871, NCT05353647). Pociredir tried to reach the same node pharmacologically. Inhibiting PRC2 through EED reduces the repressive H3K27me3 mark, and in erythroid precursor cells FTX-6058 lowered BCL11A transcription and translation, plausibly through effects on LIN28B (bioRxiv 2026, 10.64898/2026.02.06.704516). The disease rationale was sound, and the molecular path from EED to HbF was traceable.
What actually happened
The program did not stop for lack of an HbF mechanism. It stopped on safety, at the level of the mechanism class. The FDA placed a clinical hold on the pociredir program in 2023 over concern that the drug could raise the risk of certain blood cancers (Fierce Biotech). That concern hardened when tazemetostat, an EZH2 inhibitor that acts on the same PRC2 complex, was withdrawn from the global market in March 2026 after an unexpectedly high rate of secondary hematologic malignancies. In end-of-phase interactions, the FDA concluded that any pharmacological intervention targeting PRC2 carries comparable malignancy risk regardless of which subunit is engaged, and that this left no viable regulatory path for pociredir in sickle cell disease (Fulcrum press release, 1 June 2026). Fulcrum discontinued the program and the Phase 1 pharmacokinetic study was terminated. Open Targets records no direct EED to sickle cell disease association (score 0.0), consistent with a target reached through pharmacology rather than human genetic linkage to the disease. There are no FAERS records, since the drug never reached the market.
Failure mechanism, best guess
This is a safety signal of the on-target, whole-class kind. The liability does not come from an off-target chemical quirk of pociredir. It comes from what PRC2 does. PRC2 maintains repressive chromatin across many loci, and broad derepression in dividing hematopoietic cells is the same activity that creates malignancy risk. The tazemetostat withdrawal supplied a clinical readout of that risk for the class, and the FDA generalized from EZH2 to EED on mechanistic grounds. For a chronic, non-malignant disease such as sickle cell, where patients would take the drug for years and where gene therapy and approved HbF-independent options already exist, the tolerable excess malignancy risk is close to zero. A mechanism that may be acceptable in refractory cancer is not acceptable here, and that mismatch, not the HbF biology, ended the program.
How to prevent this next time
Two quantitative tools would have surfaced this outcome before the clinic.
First, a competitive landscape red-team analysis with an explicit benefit-risk threshold. The PRC2 class already carried a documented oncogenic-risk precedent, and tazemetostat label history was public well before 2026. A red-team would have set a quantitative tolerance, for example a target upper bound on excess malignancy hazard ratio near 1.1 for a chronic benign indication, and asked whether any PRC2-subunit inhibitor could plausibly clear it. The honest answer, given the class data, was no.
Second, historical base-rate adjustment against the validated comparator. The BCL11A-directed approaches reached 71 percent F-cells with a clean multi-year safety profile (Blood 2026, 10.1182/blood.2026033871). Benchmarking pociredir against that bar makes the trade explicit. To justify a chromatin-wide mechanism, pociredir needed to beat a direct BCL11A strategy on convenience or cost by a margin large enough to outweigh a non-zero leukemia hazard, and a quantitative number-needed-to-harm estimate against that benchmark would have shown the margin was not there. Translational validation sequencing, running long-term carcinogenicity and clonal-hematopoiesis readouts before committing to repeat-dose clinical work, would have moved this decision upstream of patient dosing.
The single highest leverage change would have been to treat PRC2 malignancy risk as a fixed class property and benchmark pociredir against direct BCL11A reactivation before any sickle cell dosing, rather than after a clinical hold and a class withdrawal forced the question.
What this means for similar programs
Epigenetic targets that act through broad chromatin remodeling inherit the safety profile of the complex, not just the molecule. EZH2, EED, SUZ12, and other PRC2 components should be treated as one risk class for chronic non-malignant indications. Picking a different subunit does not escape the liability, because the enzymatic output is shared. The Claidex Mechanism Risk Score for EED stands at 35 of 100 (yellow band), with the genetic-deficit component at the maximum 15 of 15 points, reflecting that the disease rationale here is pharmacologic and mechanistic rather than anchored in human genetics linking EED to sickle cell disease.
Open questions
Could a transient or tissue-restricted PRC2 inhibitor, dosed to avoid sustained derepression in stem and progenitor cells, ever clear the malignancy bar for a benign indication? Does the FDA position extend to all chromatin-repressive complexes or only to PRC2? And with direct BCL11A and gamma-globin approaches advancing, is there any remaining commercial space for a small-molecule HbF inducer that carries even a small leukemia signal?
Sources
- ClinicalTrials.gov, NCT07431398, Phase 1 single-dose pharmacokinetic study of pociredir, TERMINATED, enrollment 13, primary completion 2026-06-01, reason Sponsor decision: https://clinicaltrials.gov/study/NCT07431398 - Fulcrum Therapeutics announces discontinuation of pociredir program in sickle cell disease (FDA PRC2 class-risk conclusion, tazemetostat withdrawal), 1 June 2026: https://www.globenewswire.com/news-release/2026/06/01/3304708/0/en/fulcrum-therapeutics-announces-discontinuation-of-pociredir-program-in-sickle-cell-disease-and-initiation-of-strategic-review.html - FDA placed hold on Fulcrum sickle cell therapy over hematologic malignancy concerns (2023 clinical hold), Fierce Biotech: https://www.fiercebiotech.com/biotech/fda-placed-hold-fulcrums-sickle-cell-therapy-over-hematological-malignancy-concerns - Long-term stability of BCL11A silencing with a shmiR vector in sickle cell disease (71 percent F-cells, 11.9 pg HbF per F-cell, stable at least 48 months), Blood 2026, NCT05353647: https://- Regulation of BCL11A in HUDEP-2 cells, FTX-6058 reduces BCL11A via LIN28B, bioRxiv 2026: https://- Identification of RBM3 as a regulator of human fetal hemoglobin expression, Int Immunopharmacol 2025: https://- Modeling therapeutic targets in beta-globin disorders, Adv Exp Med Biol 2026: https://- Open Targets, EED target profile (no direct EED to sickle cell disease association, score 0.0): https://platform.opentargets.org/target/ENSG00000074266.